Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia
Abstract Second-generation antipsychotics have demonstrated efficacy for patients with schizophrenia but are associated with wide-ranging side effects. Brexpiprazole, a serotonin-dopamine activity modulator, has demonstrated efficacy